A detailed history of Barclays PLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 476,672 shares of BCRX stock, worth $3.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
476,672
Previous 476,672 -0.0%
Holding current value
$3.57 Million
Previous $3.62 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$6.41 - $8.69 $1.6 Million - $2.17 Million
250,086 Added 110.37%
476,672 $3.62 Million
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $205,145 - $337,272
-49,672 Reduced 17.98%
226,586 $1.4 Million
Q1 2024

May 15, 2024

SELL
$4.89 - $7.65 $2.09 Million - $3.28 Million
-428,271 Reduced 60.79%
276,258 $1.4 Million
Q4 2023

Feb 15, 2024

BUY
$4.98 - $6.77 $782,860 - $1.06 Million
157,201 Added 28.72%
704,529 $4.22 Million
Q3 2023

Nov 07, 2023

SELL
$6.71 - $7.92 $16,177 - $19,095
-2,411 Reduced 0.44%
547,328 $3.88 Million
Q2 2023

Aug 03, 2023

SELL
$6.96 - $8.81 $1.07 Million - $1.35 Million
-153,434 Reduced 21.82%
549,739 $3.87 Million
Q1 2023

May 04, 2023

BUY
$7.94 - $11.84 $1.74 Million - $2.59 Million
218,681 Added 45.14%
703,173 $5.86 Million
Q4 2022

Feb 13, 2023

BUY
$10.5 - $14.2 $766,248 - $1.04 Million
72,976 Added 17.73%
484,492 $5.56 Million
Q3 2022

Nov 03, 2022

BUY
$10.79 - $14.81 $3.5 Million - $4.81 Million
324,633 Added 373.64%
411,516 $5.18 Million
Q2 2022

Aug 12, 2022

SELL
$7.89 - $17.88 $279,653 - $633,738
-35,444 Reduced 28.97%
86,883 $918,000
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $1.11 Million - $1.9 Million
-96,205 Reduced 44.02%
122,327 $1.99 Million
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $1.56 Million - $2.16 Million
139,616 Added 176.92%
218,532 $3.03 Million
Q3 2021

Nov 09, 2021

SELL
$14.21 - $17.65 $46,225 - $57,415
-3,253 Reduced 3.96%
78,916 $1.13 Million
Q2 2021

Aug 13, 2021

SELL
$9.5 - $17.24 $1.45 Million - $2.64 Million
-153,124 Reduced 65.08%
82,169 $1.3 Million
Q1 2021

May 13, 2021

BUY
$7.37 - $13.61 $1.01 Million - $1.87 Million
137,263 Added 140.02%
235,293 $2.39 Million
Q4 2020

Feb 11, 2021

SELL
$3.37 - $8.61 $639,204 - $1.63 Million
-189,675 Reduced 65.93%
98,030 $730,000
Q3 2020

Nov 12, 2020

SELL
$3.43 - $5.53 $295,000 - $475,613
-86,006 Reduced 23.01%
287,705 $987,000
Q2 2020

Aug 12, 2020

SELL
$1.9 - $5.61 $1.47 Million - $4.35 Million
-775,135 Reduced 67.47%
373,711 $1.78 Million
Q1 2020

May 13, 2020

BUY
$1.6 - $4.11 $1.52 Million - $3.9 Million
949,442 Added 476.14%
1,148,846 $2.3 Million
Q4 2019

Feb 10, 2020

SELL
$1.59 - $3.45 $53,745 - $116,616
-33,802 Reduced 14.49%
199,404 $688,000
Q3 2019

Nov 14, 2019

SELL
$2.5 - $3.73 $319,077 - $476,063
-127,631 Reduced 35.37%
233,206 $669,000
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $742,084 - $2.33 Million
255,012 Added 240.98%
360,837 $1.37 Million
Q1 2019

May 15, 2019

BUY
$7.38 - $9.72 $478,895 - $630,740
64,891 Added 158.53%
105,825 $861,000
Q4 2018

Feb 14, 2019

SELL
$6.51 - $9.6 $27,433 - $40,454
-4,214 Reduced 9.33%
40,934 $330,000
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $187,956 - $272,059
34,050 Added 306.81%
45,148 $345,000
Q2 2018

Aug 14, 2018

SELL
$4.6 - $6.52 $84,529 - $119,811
-18,376 Reduced 62.35%
11,098 $64,000
Q1 2018

May 15, 2018

BUY
$4.35 - $5.82 $25,234 - $33,761
5,801 Added 24.5%
29,474 $140,000
Q4 2017

Feb 14, 2018

BUY
$4.16 - $5.33 $36,516 - $46,786
8,778 Added 58.93%
23,673 $116,000
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $61,069 - $88,923
14,895
14,895 $78,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.